Nomic and PICI Partner to Profile Immunotherapy Responses in RADIOHEAD Study
Key Insights
Nomic Bio and the Parker Institute for Cancer Immunotherapy (PICI) are collaborating to analyze protein biomarkers in immunotherapy (search) patients.
Nomic's nELISA platform will be used to quantify hundreds of proteins in blood samples from PICI's RADIOHEAD study.
The project aims to understand how patients respond to immune checkpoint inhibitor (search) (ICI) treatment and identify resistance mechanisms.
Nomic Bio Inc. (search) and the Parker Institute for Cancer Immunotherapy (PICI) have launched a research collaboration to investigate patient responses to immunotherapy (search) across various cancer (search) types. The project will employ Nomic's nELISA high-throughput protein profiling platform to quantify circulating protein markers in approximately 3,000 blood samples from PICI’s RADIOHEAD study. This initiative aims to enhance the understanding of treatment resistance and accelerate advancements in precision medicine to improve patient care.
Large-Scale Protein Profiling for Immunotherapy Response
The collaboration focuses on PICI's RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) cohort, a prospective longitudinal study involving 1,070 patients receiving standard-of-care immune checkpoint inhibitor (search) (ICI) treatment regimens across 52 community hospitals in the United States. Nomic's nELISA platform will enable parallel quantification of hundreds of proteins related to cancer (search) and immune cell responses.
The analysis will assess the levels of inflammatory and cancer (search)-related proteins and explore their association with patient response to therapy, survival rates, and the likelihood of developing immune-related adverse events. This comprehensive approach seeks to elucidate the communication pathways among immune cells in response to disease states and treatments.
nELISA Platform for Enhanced Proteomics
Nomic's nELISA platform offers industry-leading specificity and delivers absolute quantification of numerous key protein targets. This technology, combined with high throughput, positions Nomic as a leading proteomics solution provider in drug discovery. The platform's capabilities are expected to provide valuable insights into the mechanisms driving immunotherapy (search) responses.
Expected Outcomes and Impact
The collaboration aims to identify clinically actionable mechanisms for CPI resistance and adverse events, discover targets for combination therapies and post-CPI treatment, and inform system biology approaches to elucidate disease pathways. Nomic and PICI anticipate publishing data generated by the study in early 2025. The findings are expected to help healthcare providers make more informed decisions about life-saving immunotherapies.
According to Tarak Mody, PhD, chief business officer at PICI, characterizing the soluble signaling molecules of longitudinal patient samples will help elucidate the communication pathways among immune cells. Milad Dagher, CEO and Co-Founder of Nomic, emphasized that this collaboration is a great opportunity to apply their nELISA technology to improve patients’ lives by helping healthcare providers make more informed decisions about immunotherapies.